Table 4.
Clinical and demographic characteristics of the study participants with PTSD symptoms, compared to those without PTSD symptoms and healthy controls.
| Total cohort (n = 198) |
PTSD symptoms (n = 16) |
PTSD ctrls (n = 182) |
Healthy controls (n = 106) |
PTSD vs PTSD ctrls |
PTSD vs healthy ctrls |
|||||||||
| mean±SD |
|
mean±SD |
mean±SD |
mean±SD |
|
p-value | p-value | |||||||
|
median |
(IQR) |
median |
(IQR) |
median |
(IQR) |
median |
(IQR) |
|||||||
| |
n (%) |
|
n (%) |
n (%) |
|
n (%) |
|
|
||||||
| Age | 37 | (30.0– 43.0) | 35± 10.0 | 37 | (30.0– 43.0) | 38 | (30– 44) | NS | NS | |||||
| Female | 139 (70%) | 13 (81%) | 126 (69%) | 71 (67%) | NS | NS | ||||||||
| Weight | 65 | (56.3– 73.0) | 59 | (52.8– 64.5) | 65 | (57.0– 73.8) | 65 | (57– 73) | NS | NS | ||||
| BMI | 22.88 | (20.7– 24.9) | 21.93 ±3.3 | 22.96 | (20.9– 25.0) | 23.02 | (21– 25) | NS | NS | |||||
| Autoimmune disease ever | 24 (12%) | 2 (13%) | 22 (12%) | 14 (13%) | NS | NS | ||||||||
| IBD IB celiacs ever | 33 (17%) | 1 (6%) | 33 (18%) | 21 (20%) | NS | NS | ||||||||
| Periodontitis ever | 44 (22%) | 5 (31%) | 39 (21%) | 22 (21%) | NS | NS | ||||||||
| Time since COVID diag months | 8.1 ±4.3 | 5 | (3.0– 5.0) | 8.43 ±4.2 | 2 | (1– 3) | < 0.05 | NS | ||||||
| Psych meds ever | 58 (29%) | 11 (69%) | 47 (26%) | 21 (20%) | < 0.001 | < 0.001 | ||||||||
| CTQ total | 31 | (27.0– 39.0) | 42.88 ±14.4 | 31 | (27.0– 38.8) | 29 | (27– 34) | < 0.05 | < 0.005 | |||||
| WHOQOL | ||||||||||||||
| DOM1 | 15.4 | (13.7– 17.1) | 14.21 ±2.9 | 15.43 | (13.7– 17.1) | 16.57 | (15– 18) | NS | < 0.01 | |||||
| DOM2 | 14.0 | (12.0– 16.0) | 11.46 ±1.9 | 14.67 | (12.7– 16.0) | 15.55 ±2 | < 0.001 | < 0.001 | ||||||
| DOM3 | 13.3 | (10.7– 16.0) | 12.5 ±3.2 | 13.33 | (10.7– 16.0) | 14.67 | (12– 17) | NS | < 0.05 | |||||
| DOM4 | 15.5 | (14.0– 17.0) | 14 ±2.6 | 15.5 | (14.5– 17.0) | 16.3 ±2 | < 0.05 | < 0.05 | ||||||
| OV QOL GH | 7.0 | (6.0– 8.0) | 6.25 ±1.6 | 7 | (6.0– 8.0) | 8 | (7– 9) | < 0.05 | < 0.05 | |||||
| PCL Total | 10.0 | (9.0– 12.0) | 43 | (38.8– 46.3) | 7 | (2.0– 17.0) | 0 | < 0.001 | < 0.001 | |||||
| CESD Total | 10 | (5.0– 19.0) | 25.13 ±9.6 | 10 | (5.0– 17.0) | 6 | (3– 10) | < 0.001 | < 0.001 | |||||
| Depressive symptoms | 32 (16%) | 9 (56%) | 23 (13%) | 0 (0%) | < 0.001 | < 0.001 | ||||||||
| STAI | ||||||||||||||
| State Total | 38 | (31.0– 46.8) | 52 (10%) | 37 | (31.0– 45.0) | 32 | (27– 36) | < 0.001 | < 0.001 | |||||
| Trait Total | 42 | (35.0– 51.0) | 55.25 ±7.2 | 41 | (35.0– 49.8) | 36 | (33– 41) | < 0.001 | < 0.001 | |||||
| State anxiety symptoms | 74 (37%) | 14 (88%) | 60 (33%) | 0 (0%) | < 0.001 | < 0.001 | ||||||||
| Trait anxiety symptoms | 81 (41%) | 16 (100%) | 65 (36%) | 0 (0%) | < 0.001 | < 0.001 | ||||||||